Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Open accessThe DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in western countries, with a median survival of 6 months and an extremely low percentage of long-term surviving patients. KRAS mutations are known to be a driver event of PDAC, but targeting mutant KRAS has proved challenging. Targeting oncogene-driven signalling pathways is a clinically validated approach for several devastating diseases. Still, despite marked tumour shrinkage, the frequency of relapse indicates that a fraction of tumour cells survives shut down of oncogenic signalling. Here we explore the role of mutant KRAS in PDAC maintenance using a recently developed inducible mouse model of mutated Kras (Kras(G12D), herein KRas) in a p53(LoxP/WT) background. We demonstrate that a subpopulation of dormant tumour cells surviving oncogene ablation (surviving cells) and responsible for tumour relapse has features of cancer stem cells and relies on oxidative phosphorylation for survival. Transcriptomic and metabolic analyses of surviving cells reveal prominent expression of genes governing mitochondrial function, autophagy and lysosome activity, as well as a strong reliance on mitochondrial respiration and a decreased dependence on glycolysis for cellular energetics. Accordingly, surviving cells show high sensitivity to oxidative phosphorylation inhibitors, which can inhibit tumour recurrence. Our integrated analyses illuminate a therapeutic strategy of combined targeting of the KRAS pathway and mitochondrial respiration to manage pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with this notion, other complex I inhibitors have shown efficacy as anti-tumor agents (Appleyard et al., 2012; Schockel et al., 2015) and may show selective toxicity against oncogene-ablation resistant cells (Viale et al., 2014) and cancer stem cells (Sancho et al., 2015).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Viale et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recurrent theme in studies on cancer progression is the increased reliance of cancer cells on OXPHOS in advanced stages of disease.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast to the proliferating bulk of a tumor, accumulating evidence suggests that quiescent subpopulations of tumor cells are markedly less glycolytic and exhibit higher dependence on oxidative phosphorylation, as well as elevated expression of mitochondrial respiratory components.”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Viale et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a mouse pancreatic cancer model, ablating oncogenic Kras from established tumors revealed a fraction of cells that survive and eventually propagate.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [103]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Self-citationTransmission Electron Microscopy
Williams, D. B., & Carter, C. B. (2009) · Springer eBooks · doi:10.1007/978-0-387-76501-3 · Cited by 3,963
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,897
Updated research nosology for HIV-associated neurocognitive disorders
Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., Clifford, D. B., Cinque, P., Epstein, L. G., Goodkin, K., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000287431.88658.8b · Cited by 2,630
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationHematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Self-citation
Cited by
Items 301–400 of 1,000
Halbrook, C. J., Thurston, G., Boyer, S., Anaraki, C., Jiménez, J. A., McCarthy, A., Steele, N. G., Kerk, S. A., Hong, H. S., Lin, L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00463-1 · Cited by 80
Self-citationMetabolic traits of cancer stem cells
Peixoto, J., & Lima, J. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033464 · Cited by 80
Dropping in on lipid droplets: insights into cellular stress and cancer
Shyu, P. T., Wong, X. F. A., Crasta, K., & Thibault, G. (2018) · Bioscience Reports · doi:10.1042/bsr20180764 · Cited by 92
Modica-Napolitano, J. S., & Weissig, V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817394 · Cited by 86
The Evolving, Multifaceted Roles of Autophagy in Cancer
Liu, J., & Debnath, J. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.005 · Cited by 86
Bustos, G., Cruz, P., Lovy, A., & Cárdenas, C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00199 · Cited by 80
Franchi, L., Monteleone, I., Hao, L.-Y., Spahr, M. A., Zhao, W., Liu, X., Demock, K. M., Kulkarni, A., Lesch, C. A., Sanchez, B., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600810 · Cited by 82
Self-citationEmerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy
Zhu, Y., Dean, A. E., Horikoshi, N., Heer, C. D., Spitz, D. R., & Gius, D. R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120844 · Cited by 86
Yang, F., Hu, A., Guo, Y., Wang, J., Li, D., Wang, X., Jin, S., Yuan, B., Cai, S., Zhou, Y., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01421-8 · Cited by 101
Tanwar, D. K., Parker, D. J., Gupta, P., Spurlock, B., Alvarez, R. D., Basu, M. K., & Mitra, K. (2016) · Oncotarget · doi:10.18632/oncotarget.11047 · Cited by 83
Stevens, B. M., Khan, N., D’Alessandro, A., Nemkov, T., Winters, A., Jones, C. L., Zhang, W., Pollyea, D. A., & Jordan, C. T. (2018) · Nature Communications · doi:10.1038/s41467-018-05984-x · Cited by 78
Photodynamic therapy regulates fate of cancer stem cells through reactive oxygen species
Zhang, Z., Wang, K., Mo, J., Xiong, L., & Wen, Y. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i7.562 · Cited by 86
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Van Ness, B., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 78
Santana-Codina, N., Chandhoke, A. S., Yu, Q., Małachowska, B., Kuljanin, M., Gikandi, A., Stańczak, M., Gableske, S., Jedrychowski, M. P., Scott, D. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.021 · Cited by 77
Mitochondrial Metabolism: Yin and Yang for Tumor Progression
Valcárcel-Jiménez, L., Gaude, E., Torrano, V., Frezza, C., & Carracedo, A. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.06.004 · Cited by 80
Hypoxia- and MicroRNA-Induced Metabolic Reprogramming of Tumor-Initiating Cells
Ullmann, P., Nurmik, M., Begaj, R., Haan, S., & Letellier, E. (2019) · Cells · doi:10.3390/cells8060528 · Cited by 77
Ikeda, K., Horie‐Inoue, K., Suzuki, T., Hobo, R., Nakasato, N., Takeda, S., & Inoue, S. (2019) · Nature Communications · doi:10.1038/s41467-019-12124-6 · Cited by 86
Cucchi, D., Camacho‐Muñoz, D., Certo, M., Pucino, V., Nicolaou, A., & Mauro, C. (2020) · Cell Stress · doi:10.15698/cst2020.01.209 · Cited by 83
Xu, L., Yin, Y., Li, Y., Chen, X., Chang, Y., Zhang, H., Liu, J., Beasley, J., McCaw, P., Zhang, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012748118 · Cited by 87
FUNDC2 promotes liver tumorigenesis by inhibiting MFN1-mediated mitochondrial fusion
Li, S., Han, S., Zhang, Q., Zhu, Y., Zhang, H., Wang, J., Zhao, Y., Zhao, J., Su, L., Li, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31187-6 · Cited by 89
Metabolic determinants of tumour initiation
Brunner, J. S., & Finley, L. W. S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00773-5 · Cited by 87
Mitochondrial immune regulation and anti-tumor immunotherapy strategies targeting mitochondria
Bai, R., & Cui, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216223 · Cited by 89
Mahadevan, K. K., LeBleu, V. S., Ramirez, E. V., Chen, Y., Li, B., Sockwell, A. M., Gagea, M., Sugimoto, H., Sthanam, L. K., Tampe, D., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.07.025 · Cited by 73
Self-citationMetastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies
Pereira, M. A., & Chio, I. I. C. (2019) · Genes · doi:10.3390/genes11010006 · Cited by 95
Mitochondria: Insights into Crucial Features to Overcome Cancer Chemoresistance
Genovese, I., Carinci, M., Modesti, L., Aguiari, G., Pinton, P., & Giorgi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094770 · Cited by 82
Mitochondrial matrix proteases: quality control and beyond
Szczepanowska, K., & Trifunović, A. (2021) · FEBS Journal · doi:10.1111/febs.15964 · Cited by 85
Redox signaling in drug-tolerant persister cells as an emerging therapeutic target
Zhang, Z., Tan, Y., Huang, C., & Wei, X. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104483 · Cited by 73
Cancer stem cells in human gastrointestinal cancer
Taniguchi, H., Moriya, C., Igarashi, H., Saitoh, A., Yamamoto, H., Adachi, Y., & Imai, K. (2016) · Cancer Science · doi:10.1111/cas.13069 · Cited by 85
TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development
Czerwińska, P., Shah, P. K., Tomczak, K. J., Klimczak, M., Mazurek, S., Sozańska, B., Biecek, P., Korski, K., Filas, V., Mackiewicz, A. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13273 · Cited by 78
Halama, A., Kuliński, M., Dib, S. S., Zaghlool, S. B., Siveen, K. S., Iskandarani, A., Zierer, J., Prabhu, K. S., Satheesh, N. J., Bhagwat, A. M., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.017 · Cited by 76
Early effects of the antineoplastic agent salinomycin on mitochondrial function
Managò, A., Leanza, L., Carraretto, L., Sassi, N., Grancara, S., Quintana–Cabrera, R., Trimarco, V., Toninello, A., Scorrano, L., Trentin, L., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.263 · Cited by 81
Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
Boukalova, S., Stursa, J., Werner, L., Ezrova, Z., Cerny, J., Bezawork-Geleta, A., Pecinova, A., Dong, L., Drahota, Z., & Neuzil, J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1021 · Cited by 74
Iron chelators target both proliferating and quiescent cancer cells
Fryknäs, M., Zhang, X., Bremberg, U., Senkowski, W., Olofsson, M. H., Brandt, P., Persson, I., D’Arcy, P., Gullbo, J., Nygren, P., et al. (2016) · Scientific Reports · doi:10.1038/srep38343 · Cited by 82
Marcucci, F., Ghezzi, P., & Rumio, C. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0573-8 · Cited by 74
Metabolic heterogeneity and adaptability in brain tumors
Badr, C. E., Silver, D. J., Siebzehnrübl, F. A., & Deleyrolle, L. P. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03569-w · Cited by 77
Namba, T., Kodama, R., Moritomo, S., Hoshino, T., & Mizushima, T. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.172 · Cited by 86
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 82
Mitochondria-centric bioenergetic characteristics in cancer stem-like cells
Shin, M., & Cheong, J. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01127-y · Cited by 75
Metabolic reprogramming and disease progression in cancer patients
Torresano, L., Nuevo‐Tapioles, C., Santacatterina, F., & Cuezva, J. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165721 · Cited by 76
Lorenzato, A., Magrì, A., Matafora, V., Audrito, V., Arcella, P., Lazzari, L., Montone, M., Lamba, S., Deaglio, S., Siena, S., et al. (2020) · Cancers · doi:10.3390/cancers12030685 · Cited by 79
Natural Agents Targeting Mitochondria in Cancer
Mani, S., Swargiary, G., & Singh, K. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21196992 · Cited by 82
Mitochondrial dynamics in cancer stem cells
Sessions, D. T., & Kashatus, D. F. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03773-2 · Cited by 76
Inhibition of mitochondrial translation suppresses glioblastoma stem cell growth
Sighel, D., Notarangelo, M., Aibara, S., Re, A., Ricci, G., Guida, M., Soldano, A., Adami, V., Ambrosini, C., Broso, F., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109024 · Cited by 76
The contributions of cancer cell metabolism to metastasis
Pascual, G., Domínguez, D., & Benitah, S. A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.032920 · Cited by 80
Fokas, E., O’Neill, E., Gordon-Weeks, A. N., Mukherjee, S., McKenna, W. G., & Muschel, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.12.001 · Cited by 88
Computational Model Predicts the Effects of Targeting Cellular Metabolism in Pancreatic Cancer
Roy, M., & Finley, S. D. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00217 · Cited by 74
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 70
Berridge, M. V., Dong, L., & Neužil, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0859 · Cited by 76
Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin
Kim, E. H., Lee, J.-H., Oh, Y., Koh, I., Shim, J., Park, J., Choi, J., Yun, M., Jeon, J. Y., Huh, Y., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now174 · Cited by 76
BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer
Chiou, S.-H., Risca, V. I., Wang, G. X., Yang, D., Grüner, B. M., Kathiria, A. S., Ma, R. K., Vaka, D., Chu, P., Kozak, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0250 · Cited by 70
Skoda, J., Borankova, K., Jansson, P. J., Huang, M., Veselská, R., & Richardson, D. R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.020 · Cited by 72
Lipid Droplets Define a Sub-Population of Breast Cancer Stem Cells
Hershey, B. J., Vazzana, R., Joppi, D., & Havas, K. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010087 · Cited by 76
Role of tyrosine phosphorylation in modulating cancer cell metabolism
Taddei, M. L., Pardella, E., Pranzini, E., Raugei, G., & Paoli, P. D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188442 · Cited by 74
Anderson, N. M., Qin, X., Finan, J. M., Lam, A., Athoe, J., Missiaen, R., Skuli, N., Kennedy, A., Saini, A. S., Tao, T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2153 · Cited by 80
Mitochondria in cancer stem cells: Achilles heel or hard armor
Zheng, X., Chen, J., Sun, Y.-B., Chen, T.-Q., Wang, J., & Yu, S. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.03.009 · Cited by 79
Targeting PIKfyve-driven lipid metabolism in pancreatic cancer
Cheng, C., Hu, J., Mannan, R., He, T., Bhattacharyya, R., Magnuson, B., Wisniewski, J. P., Peters, S., Karim, S. A., MacLean, D., et al. (2025) · Nature · doi:10.1038/s41586-025-08917-z · Cited by 86
Self-citationMitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer
Wang, Q., Li, M., Gan, Y., Jiang, S., Qiao, J., Zhang, W., Fan, Y., Shen, Y., Song, Y., Meng, Z., et al. (2020) · Theranostics · doi:10.7150/thno.38704 · Cited by 75
Autocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers
Rajbhandari, N., Lin, W.-C., Wehde, B. L., Triplett, A. A., & Wagner, K.-U. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.013 · Cited by 68
Metabolic heterogeneity in cancer: An overview and therapeutic implications
Yu, T., Gao, W., & Liu, Y. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188421 · Cited by 77
Chekulayev, V. A., Mado, K., Shevchuk, I. N., Koit, A., Kaldma, A., Klepinin, A., Timohhina, N., Tepp, K., Kandashvili, M., Ounpuu, L., et al. (2015) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2015.08.020 · Cited by 81
Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
Carew, J. S., Espitia, C. M., Zhao, W., Han, Y., Visconte, V., Phillips, J. G., & Nawrocki, S. T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1742 · Cited by 69
The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma
Ahn, A., Chatterjee, A., & Eccles, M. R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0535 · Cited by 81
Diabetes, pancreatic cancer, and metformin therapy
Gong, J., Robbins, L., Lugea, A., Waldron, R. T., Jeon, C. Y., & Pandol, S. J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00426 · Cited by 78
Li, G., Gan, Y., Fan, Y., Wu, Y., Lin, H., Song, Y., Cai, X., Yu, X., Pan, W., Yao, M., et al. (2015) · Scientific Reports · doi:10.1038/srep07856 · Cited by 78
Keoh, L. Q., Chiu, C.-F., & Ramasamy, T. S. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10956-y · Cited by 66
“As such, targeting PGC-1α has thus emerged as a prom - ising approach for disrupting CSC maintenance [75 –78 ].”
Lee, S. Y., Ju, M. K., Jeon, H. M., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1027453 · Cited by 71
Zhao, H., Wu, S., Li, H., Duan, Q., Zhang, Z., Shen, Q., Wang, C., & Yin, T. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.07.005 · Cited by 70
Therapeutic Repurposing of Biguanides in Cancer
Zhao, H., Swanson, K. D., & Zheng, B. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.03.001 · Cited by 76
Hu, L., Wang, H., Huang, L., Zhao, Y. L., & Wang, J. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9460462 · Cited by 66
Self-citationChen, W., Wang, P., Lu, Y. J., Jin, T., Lei, X., Liu, M., Zhuang, P., Liao, J., Lin, Z., Li, B., et al. (2019) · Theranostics · doi:10.7150/thno.37556 · Cited by 69
Li, X., Wang, M., Li, S., Chen, Y., Wang, M., Wu, Z., Sun, X., Yao, L., Dong, H., Song, Y., et al. (2021) · Theranostics · doi:10.7150/thno.57804 · Cited by 73
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma
Duraj, T., Kalamian, M., Zuccoli, G., Maroon, J. C., D’Agostino, D. P., Scheck, A. C., Poff, A. M., Winter, S. F., Hu, J. L., Klement, R. J., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03775-4 · Cited by 72
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 100
Vangapandu, H. V., Alston, B., Morse, J., Ayres, M., Wierda, W. G., Keating, M. J., Marszalek, J. R., & Gandhi, V. V. (2018) · Oncotarget · doi:10.18632/oncotarget.25166 · Cited by 72
Nie, K., Li, J., He, X., Wang, Y., Zhao, Q., Du, M., Sun, H., Wang, J., Lyu, J., Fang, H., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0231-2 · Cited by 64
Self-citationEvan, T., Wang, V. M.-Y., & Behrens, A. (2022) · Oncogene · doi:10.1038/s41388-022-02448-x · Cited by 79
TP53 mutation, mitochondria and cancer
Kamp, W. M., Wang, P., & Hwang, P. M. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.02.007 · Cited by 66
Waste Not, Want Not: Lactate Oxidation Fuels the TCA Cycle
Martínez‐Reyes, I., & Chandel, N. S. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.005 · Cited by 69
Targeting Redox Metabolism in Pancreatic Cancer
Hadi, N. A., Reyes‐Castellanos, G., & Carrier, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041534 · Cited by 68
Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors
Marchetti, P., Trinh, A., Khamari, R., & Kluza, J. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.01.018 · Cited by 66
Rademaker, G., Hennequière, V., Brohée, L., Nokin, M., Lovinfosse, P., Durieux, F., Gofflot, S., Bellier, J., Costanza, B., Herfs, M. F., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0287-z · Cited by 72
On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer
Penkert, J., Ripperger, T., Schieck, M., Schlegelberger, B., Steinemann, D., & Illig, T. (2016) · Oncotarget · doi:10.18632/oncotarget.11759 · Cited by 67
Feng, J., Lian, Z., Xia, X., Lu, Y., Hu, K., Zhang, Y., Liu, Y., Hu, L., Yuan, K., Sun, Z., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.023 · Cited by 71
FOXO3 is essential for CD44 expression in pancreatic cancer cells
Kumazoe, M., Takai, M., Bae, J., Hiroi, S., Huang, Y., Takamatsu, K., Won, Y., Yamashita, M., Hidaka, S., Yamashita, S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.426 · Cited by 67
NF-κB and mitochondria cross paths in cancer: mitochondrial metabolism and beyond
Capece, D., Verzella, D., Francesco, B. D., Alesse, E., Franzoso, G., & Zazzeroni, F. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.021 · Cited by 67
Farshadi, E. A., Chang, J., Sampadi, B., Doukas, M., Van 't Land, F., van der Sijde, F., Vietsch, E. E., Pothof, J., Koerkamp, B. G., & van Eijck, C. H. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1681 · Cited by 60
Mechanisms of venetoclax resistance and solutions
Liu, J., Chen, Y., Yu, L., & Yang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005659 · Cited by 76
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Park, S. J., Yoo, H. C., Ahn, E., Luo, E., Kim, Y., Sung, Y., Yu, Y. C., Kim, K., Min, D. S., Lee, H. S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2045 · Cited by 67
Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis
Nicolai, S., Pieraccioli, M., Peschiaroli, A., Melino, G., & Raschellà, G. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.354 · Cited by 70
Ullmann, P., Qureshi-Baig, K., Rodriguez, F., Ginolhac, A., Nonnenmacher, Y., Ternes, D., Weiler, J., Gäbler, K., Bahlawane, C., Hiller, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11772 · Cited by 64
Bousquet, G., Bouchtaoui, M. E., Tan, S., Lebœuf, C., de BAZELAIRE, C., Ratajczak, P., Giacchetti, S., de Roquancourt, A., Bertheau, P., Verneuil, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16925 · Cited by 66
The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance
Patil, K., Badrealam, K. F., Akhtar, S., Ahmad, A., & Shahab Uddin, M. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09979-x · Cited by 64
Mitochondrial Redox Hubs as Promising Targets for Anticancer Therapy
Ippolito, L., Giannoni, E., Chiarugi, P., & Parri, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00256 · Cited by 67
The Metabolic Heterogeneity and Flexibility of Cancer Stem Cells
Tanabe, A., & Sahara, H. (2020) · Cancers · doi:10.3390/cancers12102780 · Cited by 65
Metabolism and immunity in breast cancer
Zhang, D., Xu, X., & Ye, Q. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0793-6 · Cited by 63
Jain, A., & Bhardwaj, V. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6527 · Cited by 75
Emerging therapeutic potential of graviola and its constituents in cancers
Qazi, A. K., Siddiqui, J. A., Jahan, R., Chaudhary, S., Walker, L., Sayed, Z., Jones, D. T., Batra, S. K., & Macha, M. A. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy024 · Cited by 75
The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells
Fu, Y., Ricciardiello, F., Yang, G., Qiu, J., Huang, H., Xiao, J., Cao, Z., Zhao, F., Liu, Y., Luo, W., et al. (2021) · Cells · doi:10.3390/cells10030497 · Cited by 62
Jankú, F., Beom, S., Moon, Y. W., Kim, T. W., Shin, Y. G., Yim, D., Kim, G. M., Kim, H. S., Kim, S. Y., Cheong, J., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01277-9 · Cited by 68
Regulation of Metabolic Plasticity in Cancer Stem Cells and Implications in Cancer Therapy
Papadaki, S., & Magklara, A. (2022) · Cancers · doi:10.3390/cancers14235912 · Cited by 64
Metadata
- Authors
- Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., Kost-Alimova, M., Muller, F., Colla, S., Nezi, L., Genovese, G., Deem, A. K., Kapoor, A., Yao, W., Brunetto, E., Kang, Y., Yuan, M., Asara, J. M., Wang, Y. A., Heffernan, T. P., Kimmelman, A. C., Wang, H., Fleming, J. B., Cantley, L. C., DePinho, R. A., & Draetta, G. F.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Weill Cornell Medicine (US)
- IRCCS Ospedale San Raffaele (IT)
- Beth Israel Deaconess Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Viale, Andrea
- Draetta, Giulio F.
- ORCID
- Viale, Andrea
- Pettazzoni, Piergiorgio
- Lyssiotis, Costas A.
- Ying, Haoqiang
- Sánchez, Nora
- Marchesini, Matteo
- Carugo, Alessandro
- Seth, Sahil
- Giuliani, Virginia
- Colla, Simona
- Nezi, Luigi
- Genovese, Giannicola
- Deem, Angela K.
- Yao, Wantong
- Brunetto, Emanuela
- Kang, Ya’an
- Yuan, Min
- Asara, John M.
- Wang, Y. Alan
- Heffernan, Timothy P.
- Kimmelman, Alec C.
- Wang, Huamin
- Fleming, Jason B.
- Cantley, Lewis C.
- DePinho, Ronald A.
- Draetta, Giulio F.
- Venue
- Nature
- Published
- 2014-08-10
- Volume
- 514
- Issue
- 7524
- Pages
- 628-632
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4376130
- OpenAlex
- W2023300506
- Semantic Scholar
- 819eeeb41f6e84dd5c00221a269e91238736c4ad
- Cited by
- 1,259
- References
- 125
- Citations by year
- 2026: 93 · 2025: 72 · 2024: 104 · 2023: 105 · 2022: 119 · 2021: 131 · 2020: 135 · 2019: 114 · 2018: 105 · 2017: 90 · 2016: 99 · 2015: 81 · 2014: 8
- FWCI
- 44.61
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-04-08)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P50CA127003, CA-16672, CA 016672, P01CA120964, P30CA016672, P01CA117969)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- pancreatic ductal adenocarcinoma, KRAS mutation, tumor recurrence, oxidative phosphorylation, mitochondrial respiration, cancer stem cells, autophagy, glycolysis, OXPHOS inhibitors, combination therapy
- MeSH terms
- Animals, Autophagy, Cell Survival, Disease Models, Animal, Female, Glycolysis, Lysosomes, Mitochondria, Mutation, Neoplasm Recurrence, Local, Oxidative Phosphorylation, Pancreatic Neoplasms, Recurrence, Neoplastic Stem Cells, Signal Transduction, Gene Expression Regulation, Neoplastic, Genes, p53, Proto-Oncogene Proteins p21(ras), Cell Respiration, Carcinoma, Pancreatic Ductal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.